Aug 6 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* AURINIA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* AURINIA PHARMACEUTICALS INC - INITIATING AUDREY™ PHASE 2/3 CLINICAL STUDY FOR VOS IN DRY EYE SYNDROME
* AURINIA PHARMACEUTICALS INC - FULLY-ENROLLED AURORA PHASE 3 TRIAL IN LUPUS NEPHRITIS CONTINUES ON TRACK WITH RESULTS ANTICIPATED IN LATE 2019
* AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.17